BREAK THIS PRACTICE HABIT

To scan or not to scan: Routine ultrasonography is not necessary after medication management of early pregnancy loss

Author and Disclosure Information

The authors contend that patients should be offered the option of a phone check-in and home pregnancy testing after medication management of miscarriage


 

References

CASE Patient finds that follow-up ultrasonography is burdensome

Ms. MB presents to the clinic for dating ultrasonography and is diagnosed with a missed abortion measuring 7 weeks. After reviewing her management options, she elects for medication management. She receives mifepristone 200 mg and misoprostol 800 µg, with a plan to follow-up in clinic for repeat ultrasonography in a week. The day of her follow-up appointment, there is a large snowstorm. She calls her care team to ask if she needs to have a follow-up visit, as she is certain she has passed tissue and her bleeding is now minimal. She is told, however, that a follow-up ultrasonography is required, per clinic policy, to ensure successful management. Despite Ms. MB’s grief and the difficult travel conditions, she makes the arduous journey back to the clinic to complete the ultrasound.

Do all patients need an ultrasound after medication management of early pregnancy loss? Or is there an alternative follow-up option?

Early pregnancy loss (EPL) is a common pregnancy complication, and its management is a routine part of reproductive health care. In the clinically stable patient, EPL may be managed expectantly, surgically, or medically, based on the patient’s preference. For patients who select medication management, clear evidence supports that a combination regimen of mifepristone and misoprostol is more effective than treatment with misoprostol alone.1,2 The data suggest that 91% of patients will experience expulsion of the gestational sac by 30 days with medication management.1 Because a minority of patients will have a retained gestational sac despite medication therapy, follow-up ensures complete expulsion of pregnancy tissue.

In the United States, most follow-up protocols include an ultrasound examination, which often entails transvaginal ultrasonography. Returning to clinic for an additional ultrasound may be costly and inconvenient—and during a global pandemic medically risky. Further, it may undermine a fundamental principle in management of EPL: autonomy. Many patients who select medication management do so out of a desire to minimize interventions or procedures. Follow-up protocols that align with patient preferences for fewer interventions are critically important to the provision of patient-centered care. Additionally, the COVID-19 pandemic highlights the value of offering an alternative follow-up strategy that minimizes the need for additional visits to a clinic or hospital.

Lessons from medication abortion management

In many ways, follow-up after medication management of EPL is analogous to follow-up after medication abortion. In both cases, the goal of follow-up is to ensure that complete expulsion has occurred without complication and to identify patients with incomplete expulsion of pregnancy tissue who may benefit from further treatment with additional medication or uterine aspiration. A key difference in the management of EPL is that there is no concern for ongoing pregnancy.

Historically, follow-up transvaginal ultra­sonography was routinely performed after medication abortion to ensure complete expulsion of pregnancy.3 However, requiring patients to return to a health care facility for ultrasonography after abortion can be burdensome, both for patients and clinicians. To provide more accessible, patient-centered care, researchers have investigated alternative follow-up strategies for medication abortion that remove the necessity for ultrasonography. Guidelines from both the National Abortion Federation and the American College of Obstetricians and Gynecologists state that routine ultrasonography is not necessary after medication abortion.4,5

Quantitative serum human chorionic gonadotropin (hCG) testing before treatment and at a follow-up visit is one reasonable strategy to ensure successful treatment. In one study of medication abortion patients, an 80% decrease in serum hCG was predictive of complete expulsion in 98.5% of patients.6 While this strategy avoids ultrasonography, it still necessitates a visit to a health care facility for a blood draw. As an alternative, substantial evidence now demonstrates the safety and feasibility of using a combination of clinical symptoms and urine pregnancy testing to confirm completed medication abortion. The evidence for follow-up using a combination of clinical symptoms and urine pregnancy testing is discussed below.

Continue to: Symptoms...

Pages

Recommended Reading

One center’s experience delivering monochorionic twins
MDedge ObGyn
Colorectal cancer screening, 2021: An update
MDedge ObGyn
‘Reassuring’ findings for second-generation antipsychotics during pregnancy 
MDedge ObGyn
Preterm and early term birth linked to an increased risk of autism
MDedge ObGyn
Toward a clearer risk model for postpartum psychosis
MDedge ObGyn
Headache seen affecting some pregnancy outcomes
MDedge ObGyn
‘Countdown to zero’: Endocrine disruptors and worldwide sperm counts
MDedge ObGyn
COVID-19 linked to baby bust in high-income countries
MDedge ObGyn
Iron deficiency in pregnancy is common, yet many aren’t being screened for it
MDedge ObGyn
Supreme Court Case: Dobbs v Jackson Women’s Health Organization: What you need to know
MDedge ObGyn